Evidence indicates that overexpression of cyclin D1 is an important event in malignant transformation of breast cancer cells. Therefore, cyclin D1 is a potential target for mechanistically-based chemoprevention/treatment of breast cancer. Treatment of serum-stimulated quiescent MCF-7 breast cancer cells with cyclopentenone (2-cyclopenten-1-one) blocked progression through G 1 and into S phase. Growth arrest of the cyclopentenone-treated cells in G 1 was associated with changes in the levels of several proteins that control the cell cycle, including a dramatic decrease in cyclin D1 protein expression. Cyclopentenone also decreased the abundance of cyclin D1 mRNA and nuclear transcripts, indicating that it regulated cyclin D1 expression at the transcriptional level. Cyclopentenone selectively inhibited the activity of the cyclin D1 and cyclin A promoters but not the activity of several other control promoters. Deletion analysis indicated that the cyclopentenone response element was located in the cyclin D1 core promoter. Additional functional studies showed that a sequence within the core promoter (CycY, located downstream from the initiator element) played an important role in activation of the cyclin D1 promoter in MCF-7 cells. Electrophoretic mobility shift assays demonstrated speci®c binding of the transcription factor BTEB to the CycY site. The cyclopentenone response element did not correspond to the CycY site but rather mapped to the initiator element itself. The overall results suggest that cyclopentenone interferes with the transcription initiation complex that assembles over the cyclin D1 initiator element, leading to selective inhibition of cyclin D1 gene transcription.
Introduction
Transit of normal cells through G 1 and into S phase typically requires the action of mitogens, and is controlled by the cyclin dependent kinases (CDKs) that are sequentially activated by cyclins D, E and A (Morgan, 1995) . The D-type cyclins act as sensors for mitogenic growth factors (Sherr, 1996) . The key role of cyclin D1 in normal breast epithelial proliferation and development of breast cancer has been demonstrated by experiments performed with knockout and transgenic mice. In female cyclin D1 knockout mice, there is a failure of mammary gland epithelial proliferation and ascinar development during pregnancy (Sicinski et al., 1995; Fantl et al., 1995) . Conversely, targeted overexpression of cyclin D1 in the mammary gland of transgenic mice results in proliferative disturbances of mammary tissue culminating in the development of mammary adenocarcinoma . Strikingly, cyclin D1 ablation speci®cally protects against mammary carcinoma associated with activation of the Neu-Ras pathway (Yu et al., 2001) . This result strongly suggests that cyclin D1 plays an essential role in malignant transformation of a signi®cant fraction of human breast cancers.
Other evidence implicates cyclin D1 overexpression as an important event during an early stage in malignant transformation of human breast cancer cells. Overexpression of cyclin D1 mRNA (Weinstat-Saslow et al., 1995) and protein (Simpson et al., 1997; Gillett et al., 1998; Alle et al., 1998 ) is observed in 50% or more of breast ductal carcinoma in situ (DCIS) lesions, but more rarely in proliferative disease or atypical ductal hyperplasia, providing evidence that cyclin D1 overexpression plays a role during an early stage of tumor development. Increased expression of cyclin D1 is also observed in about 50% of invasive breast carcinomas by immunohistochemical staining (Barnes, 1997; Gillett et al., 1996) . In about 15 ± 20% of invasive breast carcinomas, the overexpression of cyclin D1 is caused by gene ampli®cation (Lammie et al., 1991) . The molecular mechanism(s) for overexpression of cyclin D1 in the other tumors is poorly understood. Since cyclin D1 functions as an oncogene during malignant transformation of breast cancer cells, it is a biologically signi®cant target for the rational design of new drugs to prevent/treat breast cancer.
The cyclopentenone prostaglandins (PGA 1 , PGA 2 , PGJ 2 and their metabolites) are potent inhibitors of tumor cell proliferation in vitro and are able to suppress tumorigenicity in vivo (reviewed by Straus and Glass, 2001 ). The antineoplastic activity of these compounds is thought to be related to their ability to regulate the expression of a variety of stress-induced and cell cycle related genes (Straus and Glass, 2001) . Most notably, treatment of tumor cells with these compounds results in the concerted repression of cyclin D1 and CDK4 and induction of the CDK inhibitor p21 CIP1/WAF1 , resulting in growth arrest in the G 1 phase of the cell cycle (Gorospe et al., 1996; Bui et al., 1997) .
The PGA and PGJ series prostaglandins are characterized by the presence of a cyclopentenone ring, which contains an a,b-unsaturated carbonyl group. The a,bunsaturated carbonyl group has an electrophilic center which makes these prostaglandins susceptible to undergoing an addition reaction (Michael addition) with nucleophiles such as the free sulfhydryl group of cysteine residues located in reduced glutathione (GSH) or cellular proteins (Straus and Glass, 2001) . Evidence indicates that the chemically reactive a,b-unsaturated carbonyl group is required for many of the biological actions of the cyclopentenone prostaglandins. In particular, many, if not all, of the biological activities of the cyclopentenone prostaglandins are mimicked by cyclopentenone (2-cyclopenten-1-one) itself ( Figure 1a ) (Rossi et al., 1996; Bui and Straus, 1998; Straus et al., 2000) . Cyclopentenone thus serves as a simple model compound for studying the biological activity of other Michael acceptors that contain the a,b-unsaturated carbonyl group, including the cyclopentenone prostaglandins (Straus and Glass, 2001 ) and a number of other natural and synthetic agents (Ciufolini and Zhu, 1998; Lyss et al., 1998; Suh et al., 1999) .
In the present study, we examined the eect of the model compound cyclopentenone on cell cycle progression and expression of the cyclin D1 gene in MCF-7 breast cancer cells. Cyclopentenone causes cell cycle arrest in G 1 and down-regulates cyclin D1 gene expression in these cells. Further results indicate the cyclopentenone represses cyclin D1 promoter activity and that the element that mediates this eect is located in the core promoter.
Results

Cyclopentenone blocks progression of serum-stimulated quiescent cells through G 1
Previous studies have demonstrated that the cyclopentenone prostaglandin PGA 2 causes growth arrest of C6 glioma cells (Bui et al., 1997) and MCF-7 cells (Gorospe et al., 1996) in the G 1 phase of the cell cycle. In the ®rst set of experiments, cell cycle analysis was performed to determine whether the simple model compound cyclopentenone ( Figure 1a) similarly arrested cells in G 1 . Initially, exponentially growing MCF-7 cells were rendered quiescent by culturing them in medium with 0.5% serum for a period of 40 h. FACScan analysis revealed that under these conditions, 93.3% of the cells were arrested in the G 0 /G 1 phase (Figure 1b) . The growtharrested cells were restimulated by changing to fresh medium with 10% calf serum plus DMSO vehicle or cyclopentenone and analysed after 6, 12, 24, 36 and 48 h. As shown in Figure 1b ,c, without cyclopentenone addition, serum-stimulated cells readily proceeded into the S phase. The fraction of cells in S phase reached a peak (43.4%) at 36 h. In contrast, cell cycle re-entry was strongly inhibited in cells stimulated with serum plus cyclopentenone (Figure 1b,c) . Cyclopentenone also arrested the growth of asynchronous proliferating MCF-7 cells (Figure 1d ).
Cyclopentenone regulates the expression of several proteins that control transit through G 1 and into S phase Exit of cells from G 1 is orchestrated by sequential phosphorylation of Rb by cyclin D/CDK4 and cyclin E/ CDK2 complexes (Harbour et al., 1999) . MCF-7 cells express high levels of cyclin D1 and relatively lower levels of cyclin D3, but do not express cyclin D2 (Zhou et al., 1997) . We next determined whether the block of G 1 progression was correlated with reduced expression of the D-or E-group cyclins. The results indicated that cyclopentenone severely repressed cyclin D1 protein expression (Figure 2a ). Cyclin D3 expression was also decreased in cells treated with cyclopentenone, whereas cyclin E expression was not decreased (Figure 2a) . Therefore, the arrest of cells in G 1 by cyclopentenone was correlated with repression of cyclins D1 and D3. We also determined the eect of cyclopentenone on expression of CDK4, CDK2, and the CDK inhibitor p21 CIP1/WAF1 . The results demonstrated that CDK4 expression was decreased, p21 CIP1/WAF1 expression was increased, and there was very little if any change in CDK2 expression (Figure 2a) .
The overall results presented in Figures 1 and 2a suggest that the growth arrest of cyclopentenone-treated cells in G 1 results from concerted repression of cyclin D1, D3 and CDK4 and induction of p21 CIP1/WAF1 , which inhibits cyclin E/CDK2 complexes. The remainder of this study focused on the molecular mechanism for regulation of one important target, cyclin D1. To demonstrate that the repression of cyclin D1 was a cause rather than an eect of growth arrest in G 1 , we synchronized MCF-7 cells at the beginning of S phase by treating them with hydroxyurea. Following release from the hydroxyurea block, cells slowly re-entered the cell cycle. FACScan analysis indicated that 4 h after release from the block, 37% of the cells were in S phase and that at 8 h after release from the block, 74% of the cells were in S phase (data not shown). Treatment with cyclopentenone after release of cells from the hydroxyurea block resulted in repression of cyclin D1 expression (Figure 2b ). This demonstrates that downregulation of cyclin D1 is not a secondary eect of growth arrest in G 1 .
Cyclopentenone represses cyclin D1 gene expression
As shown in Figure 3 , cyclopentenone was capable of profoundly repressing cyclin D1 mRNA levels in MCF-7 cells (lanes 4 ± 6). The existence of the two forms of cyclin D1 mRNA is due to the use of alternative polyadenylation sites (Xiong et al., 1991) . Quantitative analysis of the results by scanning densitometry indicated that the 4.1 kb species was decreased by 90% and that the 1.7 kb species was decreased by 89% (P50.05). Cyclin D3 mRNA was also decreased by 36% in the cyclopentenone-treated cells (P50.05). As a control for speci®city, we examined the eect of cyclopentenone on the expression of two housekeeping genes, ubiquitin B and C (UbB and UbC). These two genes encode polyubiquitin molecules having nine ubiquitin repeats (UbC) or three ubiquitin repeats (UbB) (Baker and Board, 1989; Nenoi et al., 1996) . In the blot shown in Figure 3 , the 3.0 kb species is the product of the UbC gene, whereas the 1.3 kb species is the product of the UbB gene (Baker and Board, 1989) . In contrast to its eect on cyclin D1 mRNA, cyclopentenone had no signi®cant eect on UbB mRNA and increased the abundance of UbC mRNA by a factor of 2.2-fold (P50.05) (Figure 3) . The results presented in Figure 3 indicated that cyclin D1 mRNA expression was severely repressed by cyclopentenone, consistent with the severe down-regulation of cyclin D1 protein. The repression of cyclin D1 gene expression was selective, as cyclin D3 mRNA was only slightly decreased, UbB mRNA was not signi®cantly changed, and UbC mRNA was increased. Changes in the steady-state abundance of a cytoplasmic mRNA can be caused by a change in transcription or a post-transcriptional change such as a change in mRNA stability. One approach for evaluating a change in transcription is to measure the level of nuclear transcripts for a speci®c gene (Straus et al., 1993 Hayden et al., 1994; Marten et al., 1994; Bui et al., 1997) . We used the technique of RT ± PCR to quantify levels of nuclear cyclin D1 transcripts that still contained intron 1 (Figure 4a,b) .
The results indicated that cyclopentenone decreased the level of cyclin D1 nuclear transcripts (Figure 4b ). This regulation was speci®c, as cyclopentenone increased the level of UbC nuclear transcripts (Figure 4b ), consistent with its eect on the steady-state level of UbC mRNA.
Cyclopentenone represses cyclin D1 promoter activity
To determine whether the repression of cyclin D1 gene expression was correlated with negative regulation of cyclin D1 promoter activity, we examined the eect of cyclopentenone on a cyclin D1/luciferase reporter and several other promoter constructs. In these experiments, we used a cyclin D1 reporter construct containing a promoter fragment extending from 71095 to +136. In all of the transfection assays, we cotransfected a pCMV ± b- CIP1/WAF1 protein expression. Lanes 1 ± 3, control cells treated with DMSO vehicle; lanes 4 ± 6, cells treated with 600 mM cyclopentenone for 24 h. (b) Regulation of cyclin D1 after release from hydroxyurea block. MCF-7 cells were arrested by treatment with hydroxyurea (10 mM) for 24 h. The cells were then washed and changed to fresh medium not containing hydroxyurea but containing DMSO vehicle or cyclopentenone (600 mM) at T=0. Incubation was continued for the indicated times, and cyclin D1 protein level was analysed by Western blotting. Each bar represents the mean of triplicate determinations+s.e. Figure 3 Eect of cyclopentenone on abundance of cyclin D1, cyclin D3 and ubiquitin mRNAs. Cells were treated with DMSO vehicle or 600 mM cyclopentenone for 24 h, and RNA was extracted from each culture. Northern blots were prepared using 15 mg of total cellular RNA per lane. Lanes 1 ± 3, control cultures treated with vehicle (DMSO) alone; lanes 4 ± 6, cultures treated with cyclopentenone galactosidase plasmid as internal control and normalized the luciferase activity to b-galactosidase activity. The activity of the promoter for two cell cycle regulatory genes, cyclin D1 and cyclin A, was repressed by cyclopentenone ( Figure 5 ). In contrast, the c-Fos, Sp1 ± TATA constructs and UAS ± LUC construct cotrans- RT ± PCR of cyclin D1 and UbC nuclear transcripts. RNA preparations from control (vehicletreated) cells and cells treated with 600 mM cyclopentenone were ampli®ed by RT ± PCR. Upper: the PCR products were subjected to electrophoresis in 1% agarose gels, Southern blotted, and probed with DNA fragments speci®c for the cyclin D1 or UbC PCR products. Lower: results of the RT ± PCR analysis were quanti®ed by scanning densitometry. Open bars, control cultures; crosshatched bars, cultures treated with cyclopentenone. Each bar represents the mean of results obtained with RNA from three dierent cultures+s.e. *Signi®cantly dierent from control mean (P50.05) fected with two other constructs containing a GAL4 DNA binding domain fused with the VP-16 or NCoA-1 activation domain showed no change in transcriptional activity ( Figure 5 ). In addition, expression of the control plasmid, pCMV ± b-gal was not signi®cantly aected by cyclopentenone treatment (data not shown). These results indicated that cyclopentenone selectively inhibited the activities of cyclin D1 and cyclin A promoters.
A diagram of the human cyclin D1 gene, showing several potential transcription factor binding sites, is shown in Figure 6a . In order to map the element that mediated the cyclopentenone response, we constructed a series of promoter deletions (Figure 6a ). The deletion constructs were transfected into MCF-7 cells to determine the eect of each deletion on promoter activity ( Figure 6b , open bars). Deletion of the interval between 71095 and 7314 resulted in a slight loss of promoter activity. Further deletion down to 797 caused a further loss of more than half of the promoter activity. Two Sp1 sites within this region have been identi®ed as positive cis-acting elements (FukamiKobayashi and Mitsui, 1998; Watanabe et al., 1998) . Finally, deletion down to 749 resulted in an additional loss of promoter activity, possibly due to deletion of a CREB/ATF binding site. Interestingly, the minimal core promoter region (749 to +136) still increased luciferase expression by about 10 ± 15-fold as compared with the promoterless pGL3 vector (Figure 6b and other results presented below), indicating that the core promoter was quite active in MCF-7 cells.
We also examined the eect of cyclopentenone on each deletion construct. All the deletion constructs were tested in the presence of 300 mM cyclopentenone (Figure 6b , cross-hatched bars), and Cyc1095 and Cyc49 were also tested in the presence of 600 mM cyclopentenone (Figure 6b, inset) . Deletion down to 749 did not result in signi®cant loss of repression of Figure 5 Eect of cyclopentenone on various luciferase reporter constructs. Each construct was transfected into MCF-7 cells along with pCMV-b-gal, and cultures were either treated (cross-hatched bars) or not treated (open bars=control) with 600 mM cyclopentenone. The identity of the constructs was as follows: CycD1, cyclin D1 (71095 to +136) promoter construct; CycA, cyclin A promoter; c-Fos, c-Fos gene promoter; Sp1 ± TATA, promoter containing three binding sites for Sp1 cloned upstream from a TATA element; UAS ± LUC, six binding sites for GAL4 cloned upstream from a TATA element. The UAS ± LUC reporter was cotransfected with expression constructs for proteins in which the GAL4 DNA binding domain was fused to the transcription activation domain of VP16 or NCoA. Each bar represents the mean of at least one experiment in triplicate. All data were normalized to b-galactosidase activity, and the mean for the control group was set at 1. Error bars represent s.e. for the pooled data 
Transcription start site of the cyclin D1 gene in MCF-7 cells
Since the cyclopentenone eect mapped within the cyclin D1 core promoter, it was important to accurately identify the cyclin D1 transcription start site in MCF-7 cells. The cyclin D1 gene has been studied independently in a number of dierent laboratories (Smith et al., 1995; Motokura and Arnold, 1993; Herber et al., 1994) ; however, the transcription start site of the cyclin D1 gene is still controversial. The cyclin D1 promoter is a TATA-less promoter. Herber et al. (1994) identi®ed an initiator-like transcription start site by RNase protection assays; however, that initiator sequence (CTCC) is dierent from the accepted initiator consensus sequence [PyPyA +1 N(T/A)PyPy, Py=pyrimidine] (Smale, 1997) . A dierent transcription start site was identi®ed by RNase protection and primer extension analyses (CCAGAGG, transcription start site is underlined) which is one bp downstream of the predicted start site for an initiator element (Motokura and Arnold, 1993; Smith et al., 1995) . In contrast, Phillip et al. (1994) reported a transcription start site located far upstream from this initiator element. Other 5' ends of cDNAs not corresponding to these start sites have also been reported (Matsushime et al., 1991) . Cellular RNAs were harvested from MCF-7 cells and subjected to 5'-RACE analysis. Two PCR products were generated (Figure 7 ), cloned and sequenced. Two independent 5'-RACE experiments were done separately. From those two experiments, ®ve clones containing the long PCR fragments and three clones containing the short PCR fragments were sequenced. The length of longer PCR product (Figure 7, arrow) is closer to the predicted product, and indeed, after sequencing, all ®ve clones containing the long PCR fragment showed a stretch of cyclin D1 sequence that started from an A (CCA-GAGG, for location within promoter sequence, see Figure 8 ). The short PCR products were the consequence of primer ligation. This result con®rmed that cyclin D1 transcription started at an initiator sequence.
Additional analysis of the 749 to +136 bp promoter interval
The nucleotide sequence of the cyclin D1 core promoter (749 to +136 interval) is illustrated in Figure 8 . As noted above, the core promoter sequence located within the interval extending from 749 to +136 constituted an active promoter element. Within this interval there are three GC-rich regions, which are reasonably well matched to the Sp1 consensus binding sequence (KRGGCGKRRY, Briggs et al., 1986) . One of the possible Sp1 binding sites is located at +71 to +82 (CycW). The second possible Sp1 binding site is located at +109 to +118 (CycX) (sequence CCCAGCCAGG on the antisense strand). The third possible site is at +124 to +134 (CycY) (sequence CAGCCCTCCCC on Figure 7 Electrophoresis of 5'-RACE products. The 5'-RACE procedure was as described in Methods. Two PCR products were seen on a 2% agarose gel. One band with a size around 140 bp (indicated by arrow) contained the sequence corresponding to the cyclin D1 5'-untranslated region. DNA markers (M) were run in the left lane, and the sizes of some fragments are indicated Figure 8 Sequence of the human cyclin D1 core promoter, extending from 749 to +136 relative to the transcription start site. The transcription start site is underlined and labeled +1. Possible binding sites for Sp1 (CycW, X and Y) and NF-kB and the endpoints of 3'-deletions Cyc49D9, D65, D96, and D121 are indicated. The sequences of the mouse and rat cyclin D1 promoter elements are shown for comparison (the Genbank accession numbers of the human, mouse and rat sequences are L09054, AF212040 and AF148946, respectively). The available rat sequence ends at position +131 the antisense strand). We next constructed a series of 3'-deletions to analyse the eect of the downstream promoter region (+1 to +136) on activity of the core promoter and to map more precisely the cyclopentenone response element. The 3'-deletion constructs contained promoter sequences from 749 to +121 (Cyc49D121), 749 to +96 (Cyc49D96), 749 to +65 (Cyc49D65) and 749 to +9 (Cyc49D9) (Figure 8 ). These constructs were transfected into MCF-7 cells, and the eect of the deletions on promoter activity was determined. Deletion of the Y site caused about a 60% loss of activity. Further deletion of X and W had little additional eect. Deletion of the region extending from +9 to +136 resulted in a complete loss of promoter activity (Figure 9) . These results suggested that there was a site located between +121 and +136 that had a positive eect on promoter activity. Interestingly, the sequence of this site is conserved 100% in human and mouse, and is also conserved within the portion of the rat sequence that is available (Figure 8 ). To investigate further the possible role of the putative Sp1 binding site Y (CycY) in activation of the cyclin D1 promoter, a mutation was introduced to eliminate this site within the context of the 749 to +136 bp cyclin D1 promoter ± luciferase reporter construct. This mutation reduced promoter activity by about 60% in comparison with the parental 749 to +136 cyclin D1 promoter ± luciferase construct (Figure 10a ). The extent of reduction of promoter activity was similar to that observed with the 749 to +121 bp promoter construct, providing further evidence that CycY is an important functional element responsible for the positive eect on cyclin D1 core promoter activity. For further con®rmation of the existence of a positively acting element between +121 to +136, additional constructs were prepared in which this sequence was cloned upstream from a minimal promoter (TATA ± LUC). Two constructs in which transcription was directed by either a single copy or multiple copies of the CycY sequence yielded an increase in luciferase expression relative to TATA ± LUC (Figure 10b ).
Binding of an Sp1-like protein to CycY site
To investigate whether nuclear protein(s) were able to bind to the CycY site, electrophoretic mobility shift assays (EMSAs) were performed, using this site as probe and nuclear proteins prepared from MCF-7 cells. A speci®c shift complex (Figure 11a ) was observed which had a faster mobility compared to an Sp1 shift complex (Figure 11a, lane 7 ). An unlabeled oligonucleotide corresponding to the +122 to +136 region of cyclin D1 promoter competed for this binding, whereas an oligonucleotide containing an Sp1 consensus sequence or an unrelated oligonucleotide corresponding to an NF-kB consensus sequence did not. Similarly, EMSAs using an Sp1 consensus sequence as probe and nuclear proteins from MCF-7 cells showed a speci®c Sp1 shift complex which was competed by unlabeled Sp1 oligonucleotide but not CycY oligonucleotide (Figure 11b ). These results indicate that MCF-7 cells contain a nuclear protein that speci®cally binds to the +122 to +136 bp oligonucleotide and does not appear to be Sp1. The major shift complex observed when MCF-7 nuclear proteins were incubated with the CycY probe ran distinctly ahead of Sp1-containing complexes in EMSA gels (Figure 11a ), suggesting that the protein(s) present in the complex were smaller than Sp1. The transcription factor BTEB (basic transcription element binding factor) binds to a sequence very similar to the Sp1 consensus sequence and is smaller than Sp1 (BTEB=244 amino acids; Sp1=788 amino acids) (Imataka et al., 1992) . We therefore performed supershift assays to determine whether the major shift complex observed with the CycY probe contained BTEB. The major CycY shift complex was partially supershifted with speci®c antibody directed against BETB, indicating that BTEB was one of the proteins present in this shift complex (Figure 11c ).
Additional analysis of the cyclopentenone effect on the cyclin D1 core promoter
To investigate whether the cyclopentenone response mapped within the Y element, the eect of cyclopentenone on a reporter with this site deleted (Cyc49D121) or altered by site-directed mutagenesis (Cyc49 Y mutant) was determined. Both of the constructs were repressed to the same extent as the Cyc49 construct, indicating that the sequence extending from +121 to +136 bp of the cyclin Figure 9 Activity of cyclin D1 3'-deletion constructs. Each of the cyclin D1 deletion constructs was transfected into MCF-7 cells along with the pCMV ± b-gal control plasmid. Luciferase and b-galactosidase activities were determined in each extract, and the luciferase activities were normalized to the b-galactosidase activities. Activity of each construct was then compared with the activity of the empty luciferase vector (pGL3). Cyc49 is the luciferase reporter construct containing the 749 to +136 promoter fragment D1 promoter was not responsible for the cyclopentenone eect ( Figure 12 ). The eect of cyclopentenone on the 3'-deletion constructs Cyc49D96 and Cyc49D65 is also illustrated in Figure 12 . Although there was a trend toward a slight decrease in the extent of repression by cyclopentenone with progressive deletion inward from the 3' end, the overall data indicate that the major cyclopentenone response element is located upstream of +65. The cyclin D1 core promoter contains a possible binding site for NF-kB (Figure 8 ) (Hinz et al., 1999) . Previous results have demonstrated that NF-kB activation and DNA binding activity are inhibited by cyclopentenone (Straus et al., 2000) . It seemed unlikely that NF-kB binding to its putative binding site in the cyclin D1 promoter played a major role in promoter activity, as NF-kB is localized to the cytoplasm rather than the nucleus of MCF-7 cells under our standard culture conditions (results not shown). Nevertheless, we tested the possibility that the NF-kB site might mediate the eect of cyclopentenone on the Cyc49 construct by mutating this site and then determining whether the cyclopentenone response was eliminated. As shown in Figure 12 , the inhibitory eect of cyclopentenone on both Cyc49 and Cyc49/NF-kB mutant was similar, indicating that NF-kB site within the Cyc49 core promoter was not responsible for the cyclopentenone eect.
Discussion
Numerous lines of evidence implicate overexpression of cyclin D1 as an early event along the pathway to malignant transformation in breast cancer. Moreover, cyclin D1 plays an essential role in malignant transformation of breast cancers induced by the neu and ras oncogenes (Yu et al., 2001) . Therefore, cyclin D1 is a potential target for the rational design of new drugs to prevent/treat breast cancer. Previous studies have shown that the cyclopentenone prostaglandins have cytostatic or cytotoxic activity toward a variety of tumor cells (Straus and Glass, 2001) . Cyclin D1 expression has been identi®ed as one target for action of these compounds (Gorospe et al., 1996; Bui et al., 1997) . We demonstrate here that the simple model compound cyclopentenone, which contains the chemically reactive a,b-unsaturated carbonyl group, blocks the progression of serum-stimulated MCF-7 cells through G 1 and represses cyclin D1 gene expression. The present results also show that cyclopentenone down-regulates the level of cyclin D1 nuclear transcripts. In addition, cyclopentenone selectively represses the activity of cyclin D1 reporter constructs in transient transfection assays. Taken together, these two results strongly implicate transcriptional repression as one mechanism for regulation of cyclin D1 gene expression by cyclopentenone. In contrast with these ®ndings, Lin et al. (2000) reported that the major mechanism for negative regulation of cyclin D1 mRNA by PGA 2 in H1299 lung carcinoma cells is mRNA destabilization. Our current results do not rule out an eect on mRNA stability, but they suggest that transcriptional regulation is also involved in regulation of cyclin D1 expression by cyclopentenone in MCF-7 cells. The dierence between our results and those reported by Lin et al. (2000) could be related to dierences in the action of cyclopentenone as compared with PGA 2 or cell type speci®c dierences in the response.
Deletion analysis indicated that the cyclopentenone response element was located in the cyclin D1 core promoter, extending from 749 to +136. Several dierent transcription start sites (Motokura and Arnold, 1993; Herber et al., 1994; Suzuki-Yagawa et al., 1997; Phillip et al., 1994) and cDNA 5' ends (Xiong et al., 1991; Matsushime et al., 1991) have been reported previously for the cyclin D1 gene in various human and rodent cell types. Therefore, it was important to identify the transcription start site in MCF-7 cells. Our results indicate that in the MCF-7 cells, cyclin D1 transcription is initiated within a sequence that matches the consensus for an initiator element, at the exact base that is predicted to be the start site (Smale, 1997) . This transcription start site is only one base pair away from one of the previously identi®ed start sites (Motokura and Arnold, 1993; Smith et al., 1995) . However, it is 14 bp upstream from the longest cDNA 5' end observed in other human tumor cells (Xiong et al., 1991) , and 50 bp downstream from the cDNA end identi®ed in mitogen-stimulated mouse macrophage cells (position 749 in Figure 8 , Matsushime et al., 1991) . It is possible that the cDNAs isolated from other human tumor cells were not quite complete. However, the start site in mouse macrophages is clearly dierent because the 5' end of the macrophage cDNAs exactly matches the mouse genomic sequence (Figure 8 , and Matsushime et al., 1991) . Therefore, it appears that real cell type or species-speci®c dierences exist in the transcription start site of the cyclin D1 gene.
The cyclin D1 core promoter element had relatively strong transcriptional activity, suggesting the presence of a positive transcription element within the core promoter region. By computer searching, we found three GC-rich sequences that resembled Sp1 binding sites within the interval extending from +1 to +136. Deletion analysis indicated that the CycY sequence, located at +122 to +136 downstream from the transcription start site, plays an important role in activating the cyclin D1 promoter. Site-directed mutagenesis of the CycY site and luciferase constructs with multimerized copies of CycY further con®rmed that this site has functional activity. It is noteworthy that the CycY sequence is conserved 100% in human and mouse, consistent with a functional role for this region. Although the CycY sequence was ®rst identi®ed as a possible Sp1 binding site, EMSA analysis showed that an oligonucleotide containing an Sp1 consensus sequence could not compete for the with the CycY probe. Lane 7 shows the shift complex formed when an Sp1 probe was incubated with MCF-7 nuclear extracts and run on the same gel. Sp1: indicates the position of a shift complex containing Sp1. (b) EMSAs were performed using MCF-7 nuclear extracts and an oligonucleotide containing an Sp1 consensus binding sequence as probe. Competitions were performed using a 100-fold molar excess of unlabeled oligonucleotide containing the Sp1 consensus binding sequence (lane 2), the CycY oligonucleotide (lane 3) or an oligonucleotide containing an NF-kB binding site (lane 5). Supershift was performed with a-Sp1 antiserum (lane 4). Although an Sp1-containing supershift complex was not observed, the a-Sp1 antiserum inhibited the DNA binding of Sp1. (c) EMSAs were performed using an oligonucleotide probe corresponding to the CycY sequence. Probe without nuclear extract was run in lane 1 and with MCF-7 nuclear extract was run in lanes 2 ± 8. Competitions were performed using a 100-fold molar excess of unlabeled CycY oligo (lane 3), and oligonucleotide containing a perfect Sp1 consensus binding site (lane 4) or an oligonucleotide containing an NF-kB binding site (lane 5). Supershifts were performed with a-BTEB antiserum (lanes 6, 7) or a-Sp1 antiserum (lane 8). Supershift: indicates the location of the supershift complex obtained with a-BTEB antiserum Figure 12 Eect of cyclopentenone on cyclin D1 reporters with an intact CycY sequence (Cyc49), with a CycY sequence altered by site-directed mutagenesis (Cyc49 Y mutant), with 3'-deletion to +121 (Cyc49D121), +96 (Cyc49D96), +65 (Cyc49D65), or with a mutant NF-kB sequence (Cyc49 NF-kB mut). Each construct was transfected into MCF-7 cells, and cultures were either treated (cross-hatched bars) or not treated (open bars=control) with 600 mM cyclopentenone. Mean results obtained with the control cultures were set at 1.0. Comparison by t-test of the extent of repression of the mutant and 3'-deletion constructs with the extent of repression of Cyc49 did not reveal any signi®cant dierences speci®c binding of MCF-7 nuclear proteins to the CycY oligonucleotide. Moreover, the migration of the speci®c complex is faster than the speci®c Sp1 complex, suggesting that an Sp1-like nuclear protein with smaller molecular weight bound to CycY. Several dierent members of the Sp family, Sp1, 2, 3, 4, and three more distantly related factors, BTEB (basic transcription element binding protein), BTEB2 and BTEB3 have been isolated (Lania et al., 1997; Martin et al., 2000) . The BTEB family is of particular interest because BTEB is smaller than Sp1, and BTEBcontaining complexes run ahead of Sp1-containing complexes in EMSA gels (Chen and Davis, 1999) . BTEB is expressed in various mammalian tissues, binds to GC-box sequences, and positively regulates gene transcription (Imataka et al., 1992; Nielsen et al., 1998) . Antibody directed against BTEB supershifted part but not all of the speci®c shift complex obtained with the CycY probe. This indicated that BTEB was one of the proteins in this complex but that other proteins with similar mobility in EMSA gels might also bind to the CycY probe.
Repression of the cyclin D1 promoter by cyclopentenone was selective. In a survey of other promoters, some like the cyclin A promoter were repressed by cyclopentenone whereas others like the c-fos promoter were not. In addition, the pCMV ± b-gal reporter used as an internal control in all transfections was not regulated by cyclopentenone. The element that mediates the repressive eect of cyclopentenone on cyclin D1 promoter activity is located in the cyclin D1 core promoter but does not correspond to the BTEB binding site or a putative NF-kB binding site. The cyclin D1 promoter lacks a TATA box but contains an initiator element. Interestingly, the cyclin A promoter is also a TATA-less promoter that has an initiator (Wang et al., 1997) . In contrast, several reporters that were not repressed by cyclopentenone, including c-Fos, Sp1-TATA and UAS ± LUC, contained a TATA box. The overall results suggest that cyclopentenone interferes with the function of one of the proteins that bind to the cyclin D1 core promoter. These include the large multisubunit complex TFIID and the RNA polymerase II holoenzyme complex itself. Mammalian core promoters are functionally diverse, and the transcription initiation complexes bound to dierent core promoters may dier in the identity/relative functional importance of proteins present within the complex. For example, the TATA-binding protein TBP is replaced by a TBP-related factor (TRF) in transcription initiation from certain promoters, the TFIID subunit TAF II 250 selectively regulates transcription of a subset of genes, and factors such as TIC2, TIC3, and NC2 activate transcription only from TATA-less promoters containing an initiator (Smale, 2001; Wang and Tjian, 1994; O'Brien and Tjian, 2000) . In this context, the molecular target for cyclopentenone is presumably a protein that is required for transcriptional activation of a subset of genes including the cyclin D1 gene.
The results presented here clearly establish that cyclopentenone blocks the progression of serumstimulated quiescent cells into S phase. The arrest in G 1 may be explained by the concerted down-regulation of cyclins D1 and D3 and CDK4, and induction of p21 CIP1/WAF1 . The major focus of the current study was the mechanism for repression of cyclin D1 expression. These results do not rule out the possibility that cyclopentenone negatively regulates other targets related to the cell cycle. In this regard, preliminary experiments have indicated that the growth arrest of asynchronous cycling cells by cyclopentenone ( Figure  1d ) is accompanied by only a slight increase in the fraction of cells in G 1 , with the remainder of the cells arrested in S or G 2 /M (data not shown). The increase in p21 CIP1/WAF1 could be contribute to growth arrest in G 2 / M by several dierent mechanisms (Taylor and Stark, 2001) . It is also possible that other, yet-to-be identi®ed, targets may be involved in growth arrest in S or G 2 /M.
In sum, we show here that like the cyclopentenone prostaglandins, the model compound cyclopentenone blocks the progression of serum-stimulated MCF-7 cells through G 1 and into S phase. Cyclin D1 expression is one target for the action of cyclopentenone and other compounds in this family. There appear to be several distinct mechanisms for regulation of cyclin D1 by this group of compounds. For example, in studies to be reported elsewhere, we have shown that treatment of MCF-7 cells with the cyclopentenone prostaglandin 15-deoxy-D 12,14 -PGJ 2 results in rapid repression of cyclin D1 translation followed by more gradual down-regulation of cyclin D1 mRNA levels (Campo, Bui, Das, Samuel and Straus, manuscript in preparation) . In the present study, we demonstrate that cyclopentenone selectively represses cyclin D1 transcription in MCF-7 cells. The target for this repression appears to be one of the protein complexes that interact with the cyclin D1 core promoter. The exact identity of this target and the molecular mechanism for repression remain as topics for future study.
Materials and methods
Materials
2-Cyclopenten-1-one (cyclopentenone) was purchased from Aldrich and diluted into argon-purged dimethyl sulfoxide (DMSO). Sp1 and NF-kB consensus double-stranded oligonucleotides were purchased from Promega (Madison, WI, USA). The Cyc122-136 (CycY) oligonucleotide had a sequence corresponding to nucleotides +122 through +136 in the cyclin D1 promoter. All the oligonucleotides used in present study were purchased from Sigma-Genosys (Woodlands, TX, USA). The BTEB antiserum was provided by Dr H Imataka, McGill University, Montreal, Canada. The mouse monoclonal Sp1 antibody (sc-420) and rabbit polyclonal cyclin D1 (sc-718), CDK4 (sc-601), CDK2 (sc-163), and p21 (sc-397) antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Rabbit polyclonal cyclin D3 antibody (AHF0152) was from Biosource International (Camarillo, CA, USA) and cyclin E antibody (06-459) was from Upstate Biotechnology (Lake Placid, NY, USA).
Cell culture
MCF-7 human breast cancer cells were obtained from American Type Culture Collection and cultured at 378C in a 7% CO 2 atmosphere in Dulbecco's modi®ed Eagle's medium (DMEM) (Mediatech Inc, Herndon, VA, USA) with 10% cosmic calf serum (CS) (HyClone, Logan, UT, USA), penicillin (100 units/ml) and streptomycin (100 mg/ml).
DNA clones
DNA clones were provided by the following individuals: the human cyclin D1 cDNA clone was from David Beach, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA (Xiong et al., 1991) ; human PRAD1/cyclin D1 genomic DNA clone was from Andrew Arnold, Massachusetts General Hospital, Boston, MA, USA (Motokura and Arnold, 1993); cyclin D3 cDNA was from Yue Xiong, University of North Carolina, Chapel Hill, NC, USA (Xiong et al., 1992) ; cyclin A and c-fos luciferase constructs were from Edith Wang, University of Washington, Seattle, WA, USA (Wang et al., 1997) . The UAS luciferase construct which contains multiple GAL4 DNA binding sites cloned upstream from a minimal promoter, and a construct containing the GAL4 DNA binding domain and the activation domain of nuclear coactivator NCoA-1 corresponding to the CBP binding domain (+830 to +984 relative to transcription start site) (McInerney et al., 1998) , were from Christopher Glass, School of Medicine, University of California, San Diego, La Jolla, CA, USA. The pH37 hamster ubiquitin cDNA was provided by Albert Fornace, National Cancer Institute, Bethesda, MD, USA, GAL4-VP16, which contains GAL4 DNA binding domain and activation domain of herpes simplex virus type 1 VP16 protein, was from Xuan Liu, University of California, Riverside, CA, USA. The Sp1 ± TATA luciferase construct has been described previously .
Construction of cyclin D1 luciferase reporter constructs
The cyclin D1 promoter luciferase reporter Cyc1095 was constructed by subcloning into pGL3-Basic an EcoRI ± PvuII restriction fragment (-1095 to +136, relative to the start site) derived the PRAD1/cyclin D1 genomic DNA clone (Motokura and Arnold, 1993) . Deletions of the cyclin D1 promoter were created by PCR, as described by Hsiang et al. (1999) , or by utilizing a XhoI restriction site (Cyc314), or by cloning a double-stranded oligonucleotide into pGL3 (Cyc49D9). Sitedirected mutagenesis was performed with the QuikChange kit from Stratagene. The sequence of the CycY mutant was CACAGCaacaaCCAG; the sequence of the NF-kB mutant was TACAGGccAcgTTTGTT (altered bases in lower case). The nucleotide sequence of each construct was veri®ed by DNA sequencing.
Western blot, Northern blot and RT ± PCR analysis
Cells were plated in 10 cm dishes at a density of 10 6 cells/ dish, cultured until 80% con¯uent, and then changed to fresh DMEM+10% CS 4 h prior to adding 600 mM cyclopentenone. An equal amount of vehicle (DMSO) was added to the culture medium of the control plates. Cells were harvested 24 h following the addition of cyclopentenone. Protein extracts were prepared and subjected to Western blot analysis as described previously, with 25 mg of protein loaded per lane (Straus et al., 2000) . Alternatively, total cellular RNA was extracted using a modi®cation of the guanidine thiocyanate method as described previously (Straus et al., 1993) . RNA (15 mg/lane) was separated by electrophoresis in 1% agarose/ formaldehyde gels and subjected to Northern blot analysis as described previously (Straus et al., 1993) . RT ± PCR analysis of nuclear transcripts was performed as described previously (Bui et al., 1997) using PCR primers based on the sequence of the cyclin D1 and UbC genes (Motokura and Arnold, 1993; Nenoi et al., 1996) . Results were quanti®ed by scanning autoradiograms with an LKB UltroScan laser densitometer (Straus et al., 1993) .
Flow cytometry analysis
Cells were plated in 10 cm dishes at a density of 8610 5 cells/ dish and grown to 60% con¯uence in DMEM+10% CS. The culture medium was aspirated, and the cells were washed once with PBS then transferred to DMEM with 0.5% calf serum for 40 h to synchronize the cells in G 0 /G 1 phase. Synchronized cells were allowed to progress through the cell cycle by changing to fresh medium+10% calf serum plus DMSO, or medium+10% calf serum plus cyclopentenone at a ®nal concentration of 600 mM. Control and cyclopentenone treated groups were processed at dierent time points after the initiation of cell cycle (Bui et al., 1997) . Cells were stained with propidium iodide and analysed by using a Becton Dickinson Immunocytometry System for relative DNA content based on red¯uorescence levels, and the distribution of cells in dierent phases of cell cycle was calculated using CellFIT software (Becton Dickinson).
Transient transfection
Transfections were performed by the calcium phosphate methods using 2 mg of luciferase reporter as described previously . Twenty hours after transfection, cells were washed with PBS, fresh medium (DMEM+10% CS) was added, and the cultures were incubated for an additional 24 h. Cells were either harvested or further treated with DMSO vehicle or cyclopentenone for an additional 20 h. All transfections were conducted in triplicate. The pCMV-b-galactosidase plasmid (pCMV-b-gal) (0.5 mg) was included in each transfection, and luciferase activity was divided by b-galactosidase activity to normalize for the transfection eciency.
5'-RACE (rapid amplification of cDNA end) 5'-RACE was performed using the Clontech Smart Race cDNA Ampli®cation Kit. 1 mg of total RNA from MCF-7 cells was used as template. PCR products were recovered from 2% low-melting agarose gel, cloned into pCR 2.1 vector (Invitrogen, Carlsbad, CA, USA), and sequenced.
Electrophoretic mobility shift assays (EMSAs)
Nuclear extracts were prepared and EMSAs were performed as described previously, using 4% polyacrylamide gels (Jiang et al., 1995; Hsiang et al., 1999) . In competition experiments, a 100-fold molar excess of unlabeled competitor oligonucleotide was added to the mix prior to the addition of nuclear protein extracts.
Statistical analysis
The signi®cance of the dierence between two means was determined by Student's t-test, using P50.05 as the cut-o for signi®cance.
